Can two drugs beat opioid relapse? new trial aims to find out
NCT ID NCT05011266
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests whether adding buprenorphine (a partial opioid) to the standard shot XR-naltrexone helps people with opioid use disorder stay in treatment and avoid relapse. 180 adults will receive either the combo or a placebo for 24 weeks. The goal is to see if the combo improves retention, reduces cravings, and boosts mood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Avery Road Treatment Center (ARTC)
RECRUITINGRockville, Maryland, 20853, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stars/Nyspi
TERMINATEDNew York, New York, 10019, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
buprenorphine/naloxone (Zubsolv) combined with extended-release naltrexone
What this could lead to
If it works, this combination could help people with opioid use disorder stay in treatment longer and reduce cravings and relapse.
What could go wrong
This is a mid-stage trial with only 180 participants, so results may not apply to everyone. Adding buprenorphine to naltrexone is a new approach and may not improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.